Antony Mattessich
Director/Board Member bei AURA BIOSCIENCES, INC.
Vermögen: 5 Mio $ am 31.03.2024
Profil
Antony Mattessich is an Independent Non-Executive Director at Aura Biosciences, Inc. He previously served as President, Chief Executive Officer & Director at Mundipharma International Ltd.
from 2009 to 2017.
From 2017 to 2024, he held the same positions at Ocular Therapeutix, Inc. Prior to that, he was the Managing Director & Director at Napp Pharmaceutical Holdings Ltd.
from 2005 to 2011.
Antony also worked at Bristol Myers Squibb Co. as the Head of Operations-International Medicines.
Before that, he was the Head-Therapeutic Franchise at Novartis AG from 2003 to 2005.
Antony completed his graduate degree at The Trustees of Columbia University in The City of New York and his undergraduate degree at the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
OCULAR THERAPEUTIX INC
0,40% | 05.02.2024 | 595 201 ( 0,40% ) | 5 Mio $ | 31.03.2024 |
AURA BIOSCIENCES INC
-.--% | 07.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Antony Mattessich
Unternehmen | Position | Beginn |
---|---|---|
AURA BIOSCIENCES, INC. | Director/Board Member | 29.09.2021 |
Ehemalige bekannte Positionen von Antony Mattessich
Unternehmen | Position | Ende |
---|---|---|
OCULAR THERAPEUTIX, INC. | Chief Executive Officer | 15.04.2024 |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 18.12.2017 |
Napp Pharmaceutical Holdings Ltd.
Napp Pharmaceutical Holdings Ltd. Pharmaceuticals: MajorHealth Technology Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 01.05.2011 |
NOVARTIS AG | Corporate Officer/Principal | 01.01.2005 |
BRISTOL-MYERS SQUIBB COMPANY | Director/Board Member | - |
Ausbildung von Antony Mattessich
The Trustees of Columbia University in The City of New York | Graduate Degree |
University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
OCULAR THERAPEUTIX, INC. | Health Technology |
AURA BIOSCIENCES, INC. | Health Technology |
NOVARTIS AG | Health Technology |
Private Unternehmen | 2 |
---|---|
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Napp Pharmaceutical Holdings Ltd.
Napp Pharmaceutical Holdings Ltd. Pharmaceuticals: MajorHealth Technology Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom. | Health Technology |